top of page
Chest Drains
Chest Drains with a
Medical Device Company
A large multi-national medical technology company sought to update the documentation for their chest drains while complying with the new EU Medical Device Regulations (EU MDR). LHF conducted a number of formative and summative studies to ensure they met this goal in addition to an aseptic presentation study that focused on the company's redesigned sterile barrier system for their chest drains. Our team has since supported this company on projects for other products in their pipeline, contributing to their ongoing usability efforts.
Industry: Medical Device
Product:
-
Chest Drains
Services Provided:
-
HF strategy
-
HF-UE plan
-
URRA development and refinement
-
Aseptic presentation study
-
Design recommendations
-
Formative and summative studies
A large, multi-national medical device company sells single-use chest drains used by healthcare providers in a variety of use environments, including the OR, the ICU, and the ER. They sought to evaluate changes they had made to the user interfaces of three of their products. These changes consisted of 1) a redesigned sterile barrier system (SBS) and 2) updated labeling and documentation that complied with the new EU Medical Device Regulation (MDR).
The EU’s MDR specifies certain requirements for labeling, and medical device manufacturers now need to become compliant with the updated requirements. Thus, our client sought to validate the usability of their updated packaging and labeling. In addition, they wanted to ensure they adhered to their own internal SOPs and quality system requirements, which had been revised to align with the latest global regulations.
LHF provided services to support our client in accomplishing these goals. We started by first developing a comprehensive strategy for evaluating the three chest drains in a way that aligned with regulatory expectations and internal SOPs. Once the scope and strategy were refined, our team developed a usability engineering (UE) plan to document the planned execution of the strategy.
We then worked closely with our client, following an iterative and cross-functional process, to develop a use-related risk analysis (URRA) that captured the critical risks associated with use of their chest drains and accompanying documentation. The URRA was the necessary foundation for any further device user interface validation as it allowed our client and team to collaboratively assess the severity and thus, the criticality of any use-related risks.
With the completion of the URRA, our team turned its focus on executing three studies to evaluate the redesigned SBS of the chest drains and assess the comprehensibility and layout of the updated labeling.
To evaluate the redesigned SBS of the chest drains, LHF designed an aseptic presentation validation study and executed it with a variety of healthcare providers to obtain diverse and representative feedback. The study involved participants demonstrating two different aseptic presentation techniques (picking and tossing), which later informed a poster created by LHF team members, Jan and Laurie, at the 2024 Annual Healthcare Symposium.
Evaluation of aseptic presentation (picking technique)
Our team then took the lead in evaluating the labeling and documentation for all three chest drains. A formative study was conducted and after a collaborative review of the design recommendations, the documentation was improved, with changes driven by user feedback and usability trends identified in both the aseptic and formative studies.
Further iterative testing was conducted on the improved labeling and documentation, culminating with a summative study. This study consisted of simulated use of critical tasks and knowledge questions. With the conclusion of the study, our team developed a summative report and identified the root causes behind any unsuccessful outcomes.
Study Setup for a Summative Labeling Comprehension Study
Our work on the chest drains project has built the foundation for a strong relationship between LHF and the Company, who has since engaged us for 10+ projects on other products in their pipeline. We look forward to our continued partnership with the Company, contributing to their ongoing efforts to provide safe, usable, and effective medical devices adhering to the latest international regulations.
bottom of page